Seres receives $125M payment from Nestlé; French biotech teases early-stage eye disease data
Seres Therapeutics, a microbiome-focused biotech, has been handed a $125 million milestone payment from Nestlé Heath Science related to the FDA approval of its C. difficile infection treatment Vowst.
Seres and Nestlé came together in 2021 to jointly commercialize the drug in the US and Canada. Following the commercialization, both companies are entitled to share equally in the profits and any losses. Seres is also eligible to receive payments of up to $225 million for certain sales milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.